OSLO, Norway & BOSTON, Mass. — Calluna Pharma AS, a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced that the first patients have been dosed in the Phase 2 AURORA study of CAL101 for IPF. AURORA is a randomized, double-blind, placebo-controlled trial designed...
treatment News
LUND, Sweden — Camurus (NASDAQ STO: CAMX) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for market authorization of Oczyesa®, octreotide subcutaneous depot (CAM2029), for the maintenance treatment in adult patients with acromegaly who have responded to and...
SAN FRANCISCO, California — Including transarterial radioembolization with Yttrium-90 (Y90-TARE) as a neoadjuvant treatment for locally advanced intrahepatic cholangiocarcinoma (CCA) may improve survival outcomes and resection rates compared with chemotherapy alone, according to the results of a recent retrospective analysis presented at the 2024 American Society of Clinical Oncology (ASCO)...
RAMAT GAN, Israel — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for the treatment of...
PETACH TIKVA, Israel — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it received a Notice of Allowance from the Canadian Intellectual Property Office for its patent application titled “An A3 Adenosine Receptor...
Ramat Gan, Israel — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that its Phase 2a study evaluating Namodenoson in patients with advanced pancreatic ductal adenocarcinoma achieved its primary safety endpoint and...
Ramat Gan, Israel — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced positive clinical data from its Phase 2a study of namodenoson in patients with advanced pancreatic cancer. The data...
Ramat Gan, Israel –– Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced results from its Phase IIa open-label study evaluating namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC)...
TORONTO, Canada – Biogen Canada Inc. is encouraged by the recent Health Technology Assessment (HTA) evaluations issued by Canada’s Drug Agency (CDA) and the Institut national d’excellence en santé et en services sociaux (INESSS) for QALSODY™ (tofersen injection), the first therapy designed to target a known genetic cause of amyotrophic lateral sclerosis (ALS). CDA Issues Positive Reimbursement...
BEIJING & CAMBRIDGE, Mass. – CANbridge Pharmaceuticals Inc., a leading China-based global rare disease-focused biopharmaceutical company committed to the research, development and commercialization of transformative therapies, announced that the Chinese National Medical Products Administration (NMPA) has approved an Investigational New Drug (IND) application for CAN106, a long-acting humanized monoclonal antibody...